Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
 
No Matching Results
Advanced search
or
Market: Market:

Vericel Corproation (VCEL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Alerts
Watch
Help
Go To:
Vericel to Present at the 2019 UBS Global Healthcare Conference on Wednesday, May 22, 2019 GlobeNewswire - Wed May 15, 7:01AM CDT
CMTX - Wed May 15, 7:01AM CDT

Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest...

VCEL : 15.96 (-2.44%)
Vericel Reports First Quarter 2019 Financial Results and Raises Full Year 2019 Revenue Guidance GlobeNewswire - Tue May 7, 7:06AM CDT
CMTX - Tue May 7, 7:06AM CDT

MACI Revenue Increased 38% Over First Quarter 2018

VCEL : 15.96 (-2.44%)
Vericel Enters into Exclusive License Agreement with MediWound for North American Rights to NexoBrid, a Biological Orphan Product for Debridement of Severe Thermal Burns GlobeNewswire - Tue May 7, 7:04AM CDT
CMTX - Tue May 7, 7:04AM CDT

Pivotal U.S. Phase 3 Clinical Study Met Primary and All Secondary Endpoints

VCEL : 15.96 (-2.44%)
MediWound Enters into Exclusive License Agreement with Vericel for Commercial Rights to NexoBrid(R) in North America GlobeNewswire - Tue May 7, 7:03AM CDT
CMTX - Tue May 7, 7:03AM CDT

$17.5 million upfront, sales royalties and up to $132.5 million in potential milestones

MDWD : 4.33 (-2.70%)
VCEL : 15.96 (-2.44%)
Will Vericel (VCEL) Report Negative Earnings Next Week? What You Should Know Zacks Equity Research - Zacks Investment Research - Tue Apr 30, 9:32AM CDT
Zacks Equity Research - ZACKS - Tue Apr 30, 9:32AM CDT

Vericel (VCEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

VCEL : 15.96 (-2.44%)
Vericel to Present at Needham Healthcare Conference GlobeNewswire - Wed Apr 3, 7:29AM CDT
CMTX - Wed Apr 3, 7:29AM CDT

Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest...

VCEL : 15.96 (-2.44%)
Market Trends Toward New Normal in Verizon Communications, Digital Turbine, Vericel, Capstead Mortgage, Paratek Pharmaceuticals, and CryoPort -- Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire - Mon Apr 1, 7:13AM CDT
CMTX - Mon Apr 1, 7:13AM CDT

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Verizon Communications Inc. (NYSE:VZ),...

CYRX : 17.02 (-3.30%)
VZ : 59.01 (+1.58%)
CMO : 8.31 (-1.19%)
APPS : 3.90 (-1.52%)
VCEL : 15.96 (-2.44%)
PRTK : 4.24 (-6.81%)
What Makes Vericel (VCEL) a New Buy Stock Zacks Equity Research - Zacks Investment Research - Wed Mar 6, 9:16AM CST
Zacks Equity Research - ZACKS - Wed Mar 6, 9:16AM CST

Vericel (VCEL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

VCEL : 15.96 (-2.44%)
Vericel to Present at Multiple Upcoming Investor Conferences GlobeNewswire - Mon Mar 4, 7:29AM CST
CMTX - Mon Mar 4, 7:29AM CST

Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced presentations at multiple upcoming investor conferences.

VCEL : 15.96 (-2.44%)
Vericel (VCEL) Tops on Q4 Earnings & Sales, Stock Up Zacks Equity Research - Zacks Investment Research - Tue Feb 26, 8:46AM CST
Zacks Equity Research - ZACKS - Tue Feb 26, 8:46AM CST

Vericel (VCEL) beat estimates for earnings as well as revenues in fourth-quarter 2018. Shares up in pre-market trading.

VCEL : 15.96 (-2.44%)
Vericel Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Full-Year 2019 Financial Guidance GlobeNewswire - Tue Feb 26, 6:29AM CST
CMTX - Tue Feb 26, 6:29AM CST

Record Quarterly Product Revenues of $31.3 Million Represent a 41% Increase Over Fourth Quarter 2017

VCEL : 15.96 (-2.44%)
What's in Store for Vericel (VCEL) This Earnings Season? Zacks Equity Research - Zacks Investment Research - Fri Feb 22, 3:43PM CST
Zacks Equity Research - ZACKS - Fri Feb 22, 3:43PM CST

On Vericel's (VCEL) fourth-quarter conference call, investor focus will be on the sales figures of the company's two approved medicines -- MACI and Epicel.

CARA : 18.21 (-4.31%)
BDSI : 4.52 (-1.09%)
VCEL : 15.96 (-2.44%)
ADRO : 3.24 (+3.51%)
Vericel to Participate in Multiple Upcoming Investor Conferences GlobeNewswire - Wed Feb 20, 7:29AM CST
CMTX - Wed Feb 20, 7:29AM CST

Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced participation in multiple upcoming investor conferences.

VCEL : 15.96 (-2.44%)
Vericel to Report Fourth-Quarter 2018 Financial Results on February 26, 2019 GlobeNewswire - Tue Feb 12, 7:29AM CST
CMTX - Tue Feb 12, 7:29AM CST

Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its fourth-quarter...

VCEL : 15.96 (-2.44%)
Vericel to Present at the 21st Annual Needham Growth Conference GlobeNewswire - Fri Jan 11, 11:11AM CST
CMTX - Fri Jan 11, 11:11AM CST

Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest...

VCEL : 15.96 (-2.44%)

Van Meerten Stock Picks

Aaon - Pick of the Day
My Stock Pick of the Day is the HVAC company AAON (AAON).
Tue Apr 23, 12:42PM CDT
AAON +0.83
See More
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
Reserve Your Spot